STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spa
The little bundle of joy was born in the early hours of 1 January, along with several others throughout the wider Andalucía region who all entered the world just as many
Intensive care nurses highlight patient isolation, fear of the unknown and using nurses who do not usually work in the ICU as key factors in caring for critical COVID-19 patients